on INVENTIVA (EPA:IVA)
Inventiva at the Guggenheim Biotech Summit 2026
Biopharmaceutical company Inventiva, listed on Euronext Paris and Nasdaq, has announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. The event will take place on February 11 and 12, 2026, in New York. Andrew Obenshain, CEO of Inventiva, will participate in a fireside chat on February 11 at 7:00 p.m. CET at the Lotte New York Palace.
Inventiva, which specializes in developing oral therapies for metabolic steatohepatitis (MASH), will use this event to hold individual meetings. The company is continuing its clinical research on lanifibranor for the treatment of this chronic liver disease.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news